Cambridge Epigenetix

Executive Summary

Cambridge Epigenetix is a private UK-based company specializing in epigenetics and genomics to develop advanced diagnostic tools for oncology and neurology. Founded in 2012 and headquartered in Cambridge, the company focuses on detecting epigenetic modifications such as DNA methylation, which are critical for early disease detection and understanding disease mechanisms. Their technologies provide high-resolution insights into genetic regulation, enabling more accurate diagnosis and monitoring of complex disorders. With a commercial-stage status and a team of 50-200 employees, the company is positioned to capitalize on the growing demand for non-invasive liquid biopsy solutions and precision medicine approaches. The company's platform has broad applications in oncology, particularly for early cancer detection and monitoring minimal residual disease, as well as in neurology for conditions like Alzheimer's. Cambridge Epigenetix benefits from the strong biotech ecosystem in Cambridge and a clear focus on differentiating its methylation-based diagnostics from competitors. While the company is private and financial details are not disclosed, its commercial stage suggests it has achieved some market traction. The key outlook hinges on expanding clinical validation, forming strategic partnerships, and scaling commercialization. Overall, Cambridge Epigenetix is a promising player in epigenetics diagnostics with potential for growth, though it faces competition from larger established players.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of pan-cancer early detection test65% success
• Q4 2026Strategic partnership for neurology diagnostic development55% success
• Q3 2026Publication of clinical validation data in a peer-reviewed journal80% success